Immatics N.V. IMTX
Immatics N.V. (Nasdaq: IMTX) is an oncology drug developer. Its lead program, anzu-cel (anzutresgene autoleucel, IMA203), is in Phase 3 for second-or-later-line advanced cutaneous melanoma (PRAME-positive); also metastatic uveal melanoma (Phase 2). Its next catalyst on record is IMA402 + IMA401 combination: IMA402 and IMA401 combination cohort in squamous NSCLC is enrolling with first data expected in 2027. (2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: IMA402 + IMA401 combination — IMA402 and IMA401 combination cohort in squamous NSCLC is enrolling with first data expected in 2027. (2027). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| anzu-cel (IMA203) - SUPRAME | 2L advanced cutaneous melanoma | cell therapy | Phase 3 |
| anzu-cel (IMA203) - uveal melanoma | metastatic uveal melanoma | cell therapy | Phase 2 |
| IMA203CD8 (GEN2) | 2L metastatic solid cancers beyond melanoma (gynecologic and others) | cell therapy | Phase 1 |
| IMA402 | PRAME-positive solid tumors incl. 2L melanoma, gynecologic cancers | protein/peptide | Phase 1 |
| anzu-cel + mRNA-4203 (Moderna PRAME cell therapy enhancer) | PRAME-positive solid tumors | cell therapy | Phase 1 |
| IMA402 + IMA401 (MAGEA4/8 bispecific) | squamous NSCLC and potentially others | protein/peptide | Pre-clinical |
Recent results and decisions
- Oct 24, 2026met IMA402 demonstrated a confirmed objective response rate of 32% (7/22) in PRAME-high melanoma with median duration of response of 12.5 months.
Treatment with IMA402 demonstrated 10 confirmed responses resulting in an overall confirmed objective response rate (cORR) of 25% (10/40) and a disease control rate (DCR) of 63% (25/40).
Filing - Oct 24, 2026positive IMA401 Phase 1 dose escalation completed with 29% cORR in head and neck cancer.
29% cORR (4/14) in head and neck cancer
Filing - Oct 24, 2026positive IMA402 Phase 1 data showed 25% confirmed ORR and 63% disease control rate with favorable tolerability in heavily pretreated solid tumors.
IMA402 showed promising anti-tumor activity as monotherapy (n=36) or in combination with an immune checkpoint inhibitor (n=4) in the efficacy population at RP2D range.
Filing
14 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 oncology companies
- Astrazeneca PLC AZN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Revolution Medicines, Inc. RVMD
- Genmab A/S GMAB
- BioNTech SE BNTX
- Guardant Health, Inc. GH
- Exelixis, Inc. EXEL
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.